PI3K/Akt Pathway Inhibition for the Treatment of Metastatic Castrate-Resistant Prostate Cancer

Описание к видео PI3K/Akt Pathway Inhibition for the Treatment of Metastatic Castrate-Resistant Prostate Cancer

David VanderWeele, MD, PhD, Assistant Professor of Medicine (Hematology and Oncology) at Northwestern University Feinberg School of Medicine, discusses the PI3K/AKT pathway and its role in cancer, PI3K/AKT pathway alterations in prostate cancer, and inhibitors of the pathway and recent clinical trial results.

Комментарии

Информация по комментариям в разработке